News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Peder Walberg appointed as interim Chief Medical Officer

January 20, 2021

Stockholm, Sweden, January 20, 2021. Egetis Therapeutics AB (publ) (ticker: EGTX) today announced that Peder Walberg will assume the role of interim Chief Medical Officer. He replaces Stefan Carlsson who has decided to leave the company to pursue other opportunities.

Peder Walberg takes on the position as interim CMO in addition to his current part time role within the company with focus on business development and the continued clinical development of the company’s lead candidate drug, Emcitate®. Peder will also continue as a member of the Board of Directors.
“The process to find a permanent CMO has been initiated. I want to take the opportunity to thank Stefan for the dedicated and professional job he has done for PledPharma and Egetis as a CMO”, said Egetis Therapeutics CEO Nicklas Westerholm.



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10